Gottlieb Condemns Pharma Exec’s Defense For Quadrupling Price Of Generic

By John Wilkerson / September 12, 2018 at 4:32 PM
FDA Commissioner Scott Gottlieb on Tuesday (Sept. 11) condemned the pharmaceutical executive who said in a Financial Times story that it was his “moral requirement” to quadruple the price of its a generic antibiotic drug nitrofurantoin to $2,392 a bottle. The publication interviewed Nirmal Mulye, CEO of Missouri-based Nostrum Laboratories , about the price increase. Mulye blamed supply shortages, and resulting price increases, on FDA’s new, stricter manufacturing rules. Gottlieb reiterated that FDA is promoting competition by speeding generic...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.